Next Article in Journal
Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response
Next Article in Special Issue
Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
Previous Article in Journal
Caregiving and Its Resulting Effects—The Care Study to Evaluate the Effects of Caregiving on Caregivers of Patients with Advanced Cancer in Singapore
Previous Article in Special Issue
Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma
Open AccessFeature PaperReview

Advances in Cancer Immunotherapy in Solid Tumors

Division of Hematology and Oncology, Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA
Department of Internal Medicine, State University of New York at Buffalo, Buffalo, NY 14228, USA
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, 14263, USA
Author to whom correspondence should be addressed.
Academic Editor: Vita Golubovskaya
Cancers 2016, 8(12), 106;
Received: 26 July 2016 / Revised: 13 November 2016 / Accepted: 13 November 2016 / Published: 24 November 2016
(This article belongs to the Special Issue Cancer Immunotherapies)
Immunotherapy is heralded as one of the most important advances in oncology. Until recently, only limited immunotherapeutic options were available in selected immunogenic cancers like melanoma and renal cell carcinomas. Nowadays, there is an improved understanding that anti-tumor immunity is controlled by a delicate balance in the tumor microenvironment between immune stimulatory and immune inhibitory pathways. Either by blocking the inhibitory pathways or stimulating the activating pathways that regulate cytotoxic lymphocytes, anti-tumor immunity can be enhanced leading to durable anti-tumor responses. Drugs which block the immune regulatory checkpoints namely the PD-1/PDL1 and CTLA 4 pathway have shown tremendous promise in a wide spectrum of solid and hematological malignancies, significantly improving overall survival in newly diagnosed and heavily pretreated patients alike. Hence there is renewed enthusiasm in the field of immune oncology with current research focused on augmenting responses to checkpoint inhibitors by combination therapy as well as studies looking at other immune modulators and adoptive T cell therapy. In this article, we highlight the key clinical advances and concepts in immunotherapy with particular emphasis on checkpoint inhibition as well as the future direction in this field. View Full-Text
Keywords: immunotherapy; immune editing; tumor microenvironment; T cell exhaustion; checkpoint inhibitors; cancer vaccines; CAR T cell therapy immunotherapy; immune editing; tumor microenvironment; T cell exhaustion; checkpoint inhibitors; cancer vaccines; CAR T cell therapy
MDPI and ACS Style

Menon, S.; Shin, S.; Dy, G. Advances in Cancer Immunotherapy in Solid Tumors. Cancers 2016, 8, 106.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop